HIV Risk Reduction in Subutex Injectors in Tbilisi

Overview

This study will obtain pilot data on the acceptability of a 12-week course of daily observed suboxone and methadone, followed by a dose taper or referral to a local treatment program for 80 opioid dependent patients (40 group) who have been injecting subutex or other buprenorphine preparations 10 or more days in the past 30, and on the impact of each medication on HIV risk and on subutex and opioid use during treatment and a followup at week 20. it will be done at the Uranti Methadone Program, affiliated with the Addiction Research Center, Union Alternative of Georgia in Tbilisi.

Full Title of Study: “Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2013

Interventions

  • Drug: methadone
    • 12 weeks of methadone maintenance with counseling
  • Drug: buprenorphine-naloxone (Suboxone) for 12 weeks
    • 12 weeks of maintenance with counseling

Arms, Groups and Cohorts

  • Active Comparator: Methadone maintenance for 12 weeks
    • Methadone maintenance for 12 weeks as compared to 12 weeks maintenance on Suboxone.
  • Active Comparator: buprenorphine-naloxone (Suboxone)
    • 12 weeks of maintenance on buprenorphine-naloxone (Suboxone) at daily doses ranging from 8 to 32 mg with counseling

Clinical Trial Outcome Measures

Primary Measures

  • Buprenorphine injecting
    • Time Frame: 12 weeks
    • 1) Obtain pilot data on the impact of a 12-week course of daily, observed Suboxone and methadone treatment on HIV injecting risk behavior, particularly that associated with injecting use of Subutex. 2) obtain pilot data on the degree to which the target population accepts treatment with daily observed Suboxone and methadone.

Secondary Measures

  • HIV Risk
    • Time Frame: 12 weeks
    • Obtain pilot data on the degree to which a 12-week course of suboxone or methadone reduces illegal activities and improves employment, psychiatric symptoms, overall adjustment and assess the prevalence of HIV, HEP B/C among study patients at week 20.

Participating in This Clinical Trial

Inclusion Criteria

  • current opioid dependence; – injecting buprenorphine 10 or more times in the last 30 days; – between 25 and 50 years of age; – buprenorphine and/or opiate positive urine test; – not on methadone maintenance in last 4 weeks; – stable address within Tbilisi and not planning to move; – home or cellular phone number where can be reached; – able to provide name of family member who knows whereabouts; – willingness and ability to give informed consent. Exclusion Criteria:

  • currently dependent on alcohol, benzodiazepines or other CNS depressants; – legan charges with impending incarceration; – plans to move from Tbilisi within next 6 months; – current participation in another treatment study; – serious medical problems that would impair or make hazardous ability to participate; – active TB; – currently psychotic/suicidal; – uncontrolled seizure disorder.

Gender Eligibility: All

Minimum Age: 25 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Pennsylvania
  • Collaborator
    • National Institute on Drug Abuse (NIDA)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Geroge Woody, MD, Study Director, University of Pennsylvania

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.